Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncotelic Therapeutics, Inc.MATN · Entity 7822 | Director | June 20, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncotelic Therapeutics, Inc.
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.22 · Expires 2024-06-20 | Direct | 258,171 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 258,171 · Balance 258,171 F1: Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy. F2: The Stock Options will vest in full on June 20, 2019, subject to Mr. Reynolds' continued service on the Board of Directors as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy.
F2: The Stock Options will vest in full on June 20, 2019, subject to Mr. Reynolds' continued service on the Board of Directors as of such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2018 Filed Jun 22, 2018 20:15 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | GrantStock Option (Right to Buy) · Derivative | 258,171 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001209191-18-039176 · doc4.xml · derivative · entry 1 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,171 Underlying: Common Stock · 258,171 shares Expires 2024-06-20 F1 · shares: Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The Stock Options will vest in full on June 20, 2019, subject to Mr. Reynolds' continued service on the Board of Directors as of such date. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:24 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock B Warrants (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-024991 · doc4.xml · derivative · entry 3 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · price: The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share. F2 · derivative.exercise_date: The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants issued pursuant to the Subscription Agreement (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date"). F3 · derivative.expiration_date: The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:24 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock A Warrants (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-024991 · doc4.xml · derivative · entry 2 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2020-04-12 F1 · price: The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:24 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock | 250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-024991 · doc4.xml · nonDerivative · entry 1 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 F1 · price: The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 00:29 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | GrantStock Option (Right to Buy) · Derivative | 121,483 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-17-039317 · doc4.xml · derivative · entry 1 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,483 Underlying: Common Stock · 121,483 shares Expires 2023-06-09 F1 · shares: Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The Stock Options will vest in full on June 9, 2018, subject to Mr. Reynolds' continued service on the Board of Directors as of such date. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:15 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock, $.01 par value per share | 9,950 | $0.36 | $3,532.25 |
DisclosureSEC source: 0001209191-16-156108 · doc4.xml · nonDerivative · entry 3 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:15 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock, $.01 par value per share | 7,350 | $0.35 | $2,572.50 |
DisclosureSEC source: 0001209191-16-156108 · doc4.xml · nonDerivative · entry 2 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,050 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:15 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock, $.01 par value per share | 12,700 | $0.34 | $4,318.00 |
DisclosureSEC source: 0001209191-16-156108 · doc4.xml · nonDerivative · entry 1 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 20:24 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | GrantStock Option (Right to Buy) · Derivative | 135,612 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001209191-16-147149 · doc4.xml · derivative · entry 1 Reynolds Donald Rogers · CIK 0001687930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,612 Underlying: Common Stock · 135,612 shares Expires 2022-10-25 F1 · shares: Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "Stock Options"), in connection with his appointment to the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Director Compensation Policy. F2 · derivative.exercise_date: The Stock Options will vest in three equal annual installments on the first, second and third anniversary of the date of grant, subject to Mr. Reynolds' continued service on the Board of Directors as of such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.